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Background: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is
poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but
little evidence exists to guide practice.
Method: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were
recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the
EQ-5D, EORTC QLQ-C30 and LC13.
Results: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC).
Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the
BSC group whose overall HRQoL fell (P¼ 0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective
of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P¼ 0.012). Additionally,
those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.
Conclusions: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is
initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.
Malignant pleural mesothelioma (MPM) is a heterogenous
malignancy with the majority of patients following a rapidly
progressive disease course. It often presents with troublesome
and distressing symptoms that are difficult to control clinically
and worsen with disease progression. Treatment options
are limited and survival is poor, with a median life expectancy
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of 9–14 months from diagnosis (Yates et al, 1997; Chapman
et al, 2008).
Randomised trial data has demonstrated survival benefits using
antifolates (namely pemetrexed or raltitrexed) in combination with
platinum-based cytotoxics (cisplatin or carboplatin), adding
around 2 months of overall survival and reducing time to
progression (Vogelzang et al, 2003). However, in the United
Kingdom the proportion of patients offered chemotherapy varies
widely between centres (HSCIC HaSCIC, 2014). Given the modest
survival benefit, the focus of treatment remains palliative with an
emphasis on preserving quality of life.
Trial data examining the impact of chemotherapy on health-
related quality of life (HRQoL) is limited (Boons et al, 2013).
Where HRQoL has been formally assessed, some studies do report
an improvement in disease-specific symptoms (e.g., dyspnoea)
(Bottomley et al, 2006). However, due to concurrent treatment side
effects, no studies have demonstrated a benefit in overall HRQoL
with chemotherapy (Muers et al, 2004). Additionally, given
variable response to treatment there is an emphasis on individua-
lised prognostic information at baseline and early disease response
evaluation to inform future therapy. Currently, serial CT findings
are used to assess treatment response (Byrne & Nowak, 2004), but
this approach has a no evidence base for predicting HRQoL
outcomes.
The South West Area Mesothelioma and Pemetrexed (SWAMP)
trial was designed to examine the relationship between baseline
and serial radiological, biochemical or demographic factors and
survival or chemotherapy response (Hooper et al, 2015). This sub-
study analyses similar factors but with a focus on HRQoL in an
attempt to inform oncologists as to which patients might benefit
most from chemotherapy.
PATIENTS AND METHODS
Study design. The SWAMP study is a large multi-centre
prospective observational study evaluating biomarkers and radi-
ological techniques as predictors of MPM tumour response to first-
line chemotherapy (pemetrexed and cisplatin/carboplatin). The
trial included a ‘comparator’ group of patients with similar
performance status who, although deemed fit for chemotherapy,
declined chemotherapeutic treatment after consultation with an
oncologist. Detailed study inclusion criterion and methods can be
found in the primary paper.
This sub-study focussed on the HRQoL outcomes from the
SWAMP study.
HRQOL data collection. HRQoL of patients was assessed at five
different time points (baseline, 6 weeks, 16 weeks, 12 months and
18 months). The patients completed the questionnaires for the first
two time points (at baseline and 6 weeks) under the direct
supervision of either the trial co-ordinator or the trial research
nurse to ensure understanding. Subsequent questionnaires were
posted to the patients to complete at home. Three different HRQoL
measures were used at each time point, namely, the EQ-5D,
EORTC QLQ-C30 and EORTC LC13.
The EQ-5D is a widely used preference-based generic HRQoL
instrument and is the instrument favoured by NICE (National
Institute of Health and Care Excellence) (Longworth & Rowen,
2013). It measures HRQoL on 5 dimensions (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression) with 3
severity levels for each dimension, producing a possible 243 health
states. A utility score can be generated for each health state by
applying country-specific general population-elicited tariffs, which
can then be used to calculate quality-adjusted life years. This data
set used the UK population EQ-5D tariff (Dolan, 1997). Apart
from a recently published randomised controlled trial of partial
pleurectomy vs talc pleurodesis, we found no other use of the EQ-
5D in MPM (Rintoul et al, 2014).
The EORTC QLQ-C30 (version 3) is a disease-specific
questionnaire developed specifically for use in cancer. There are
five functional scales (physical, role, emotional, cognitive and
social), a global health item, three symptom scales (fatigue, nausea/
vomiting and pain) and single symptom items (dyspnoea, appetite
loss, constipation, diarrhoea and financial difficulties). All items
are converted onto a 0–100 scale. It is important to note that higher
scores for the global health and functional categories indicate
higher functioning, whereas higher symptom scores denote worse
symptomatology.There are a total of 30 questions in an attempt to
give a broad and sensitive assessment of HRQoL in patients with
cancer (Aaronson et al, 1993). It was validated for use in MPM by
Nowak et al (2004) after showing predictive validity for survival
and a correlation with spirometry findings.
The EORTC QLQ-LC13 was designed specifically for use in
lung cancer patients undergoing chemotherapy or radiotherapy
(Bergman et al, 1994). It contains 13 items that relate to lung
cancer-specific symptomatology and treatment side effects, for
example, cough, haemoptysis, sore mouth and peripheral neuro-
pathy. Higher scores (from 0 to 100) denote worse symptoms. This
instrument was also validated for MPM after demonstrating a
strong relationship between survival and patient-reported pain
(Nowak et al, 2004).
Statistical analysis. The SWAMP trial was powered for the
primary end point of ‘difference in time to progression on serial
CT scan between patients demonstrating a metabolic response to
chemotherapy on interval PET-CT vs those demonstrating no
metabolic response’.
Changes across time within the various dimensions of the
HRQoL instruments were assessed using Wilcoxon signed rank-
sum test. To minimise type I errors in the comparison of multiple
factors, the level of statistical significance was set at P¼ 0.01 for
this analysis. Analysis of co-variance (ANCOVA) was used to
assess change in HRQoL from baseline between relevant clinical
subtypes. An intent-to-treat principle was used to compare the
chemotherapy and comparator groups, that is, once the decision
was made not to have chemotherapy (at study entry), there was no
cross-over between groups at later time points. To investigate the
impact of missing HRQoL data, a sensitivity analysis was
performed to investigate the probability of missing values (by
drop out) for significant clinical factors. Any association between
clinical group and missing data was assessed using Fisher’s exact
test. Finally, given the previously limited use of EQ-5D in MPM, a
Cox proportional hazards regression analysis was used to assess its
ability to predict survival.
Trial funding and support. The trial was funded through an
unrestricted educational grant from the Cobalt Appeal Fund,
Cheltenham, UK.
Ethical approval and registration. Ethical and regulatory
approval for the study was obtained before recruitment commenced
(UK REC Reference: 08/H0102/46). The trial was registered in the
national portfolio (UKCRN ID: 8450).
RESULTS
Primary study findings. The main clinical findings of the
SWAMP trial have been reported in the primary paper. At
baseline, a neutrophil/lymphocyte ratio of 44, total glycolytic
volume on PET-CT of 41800 and non-epithelioid histology
inferred a poor prognosis (P¼ 0.002, 0.001 and o0.001,
respectively). Change in serial mesothelin was shown to predict
disease stability on CT as well as overall survival.
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Baseline data. Between September 2008 and December 2011, 73
patients with treatment-naive pleural mesothelioma were recruited
from seven different centres in the South West of England. Patients
were required to be in WHO performance stage 0, 1 or 2 and not
have received previous chemotherapy. Of the 73 patients, 15
declined chemotherapy after discussion with their oncologist
creating ‘comparator’ group. Table 1 summarises the baseline
demographics and HRQoL of the study participants.
The comparator groups were an older cohort (median age 78 vs
69 years) with proportionally fewer patients with a performance
status of 0 (29% vs 13%). The chemotherapy and comparator
groups were comparable with respect to HRQoL at baseline with
no significant differences between them in any of the EQ-5D,
QLQ-C30 or QLQ-LC13 dimensions. Baseline data showed that
the entire cohort had significant disutility with a mean EQ-5D
of 0.69 (range;  0.595 to 1) and QLQ-C30 global health of 65
(range, 0–100). The most marked deficiencies in the functional
scales was in role function, and in the symptom scales, patients
suffered from considerable fatigue, dyspnoea, insomnia and cough.
Two HRQoL dimensions were shown to be baseline positive
predictors of survival – a higher EQ-5D score (P¼ 0.026) and
lower dyspnoea (i.e., less breathlessness) measured by the LC13
(P¼ 0.010) using Cox proportional hazards modelling.
Compliance with HRQoL questionnaires. Table 2 summarises
the compliance with the HRQoL questionnaires over the course of
the study.Only one questionnaire was not returned at baseline,
equivalent to 98% completion but compliance fell over time. The
number of forms received fell from 82% at 6 weeks to 58% at
12 months. Given natural attrition due to patient death and falling
compliance, the authors decided to limit statistical analysis to
visit 3.
Table 1. Baseline characteristics
Chemotherapy
(n¼58), No. (%)
Comparator
(n¼15), No. (%)
Total
(n¼73), No. (%)
Age, years
Median 69 77 69
Range 40–83 65–89 40–89
Sex
Male 52 (90) 11 (73) 63
Female 6 (10) 4 (27) 10
Histological subtype
Epithelioid 39 (67) 11 (73) 50
Biphasic 4 (7) 0 (0) 4
Sarcomatoid 15 (26) 4 (26) 19
WHO performance status
0 17 2 19
1–2 41 13 54
Biochemistry
Neutrophil/lymphocyte 5.5 4.5 5.3
Mesothelin 6.6 6.0 6.5
Mean (s.d.) Mean (s.d.) Mean (s.d.)
EQ-5D (range 0.595 to 1) 0.688 (0.252) 0.710 (0.268) 0.692 (0.254)
QLQ-C30 (range 0–100)
Global function 63 (21) 72 (17) 65 (20)
Physical function 74 (19) 73 (20) 73 (19)
Role function 63 (32) 60 (38) 62 (33)
Emotional function 77 (23) 87 (20) 79 (23)
Cognitive function 82 (24) 82 (19) 82 (24)
Social function (range 100–0) 71 (26) 73 (38) 71 (29)
Fatigue 37 (22) 34 (23) 36 (22)
Pain 26 (25) 18 (21) 24 (25)
N and V 8 (13) 7 (12) 8 (13)
Dyspnoea 45 (29) 38 (21) 43 (28)
Insomnia 33 (33) 19 (28) 30 (33)
Appetite loss 23 (29) 36 (39) 25 (32)
Constipation 18 (27) 27 (34) 20 (29)
Diarrhoea 6 (16) 4 (11) 6 (15)
Financial problems 16 (29) 7 (19) 14 (28)
QLQ-LC13 (range 100–0)
Dyspnoea 33 (23) 36 (18) 34 (22)
Coughing 31 (22) 27 (26) 30 (23)
Haemoptysis 2 (10) 0 (0) 1 (9)
Sore mouth 4 (13) 0 (0) 3 (11)
Dysphagia 7 (16) 4 (12) 6 (16)
Peripheral neuropathy 6 (16) 7 (19) 6 (16)
Alopecia 2 (10) 2 (9) 2 (10)
Pain in chest 22 (26) 24 (32) 23 (27)
Pain in arm 18 (25) 13 (17) 17 (24)
Pain (other) 18 (26) 10 (16) 16 (25)
Abbreviations: N and V¼nausea and vomiting; WHO¼World Health Organisation.
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Chemotherapy vs comparator group. There were significant
differences between the chemotherapy and comparator groups
over time, despite comparable HRQoL at baseline. Most notably in
overall health measured by the EQ-5D where the chemotherapy
group maintained overall health throughout whereas the com-
parator group worsened considerably, so that by time point 3 the
difference between them using the ANCOVA approach was
significant (P¼ 0.006). Figure 1 demonstrates the change in mean
EQ-5D from baseline to 16 weeks between the chemotherapy and
comparator arms divided by histological subtype. For the EORTC
instruments, the Wilcoxon signed ranked test was used to
investigate change in functional and symptom scales from baseline.
Any dimensions that changed significantly (Po0.01) are repre-
sented graphically in Figure 2. General worsening of global health,
physical function and fatigue were seen across the cohort. At visit
2, the chemotherapy group experienced worsening social function
as well as worsening symptoms of nausea and vomiting and sore
mouth. At visit 3, these functional and symptoms scores had
resolved but alopecia had worsened significantly. The comparator
group did not suffer from the same gastrointestinal symptoms or
alopecia but, at visit 3, had significantly worse dyspnoea and arm
pain compared with baseline.
Chemotherapy group. The following analyses use only the
chemotherapy arm (n¼ 58). Table 3 shows the effect of
demographic, tumour and biochemical factors on HRQoL. This
analysis focussed on results from the EQ-5D. An independent
samples T-test showed no significant differences between the
groups at baseline. An ANCOVA method was used to assess the
change in HRQoL from baseline to 16 weeks. Those with non-
epithelioid histology had a decline in HRQoL and the variance
from baseline between the groups was significant, although the
same pattern was seen in the comparator group (see Figure 1).
Serum mesothelin was measured at baseline and visit 2, a rising or
falling mesothelin was not subject to any thresholds. Patients with
a falling mesothelin at visit 2 compared with baseline had an
improvement in HRQoL compared with those with a rising
mesothelin (see Figure 3). Disease response on serial CT imaging
(using RECIST criteria) at 8 weeks was also positively correlated
with HRQoL (see Figure 4).
Sensitivity analysis. The sensitivity analysis showed no differences
in the proportion of missing results between any of the clinical
groups tested, supporting our main findings. Clinical groups
examined included chemotherapy vs comparator (P¼ 0.75), age
470 vs ageo 70 (P¼ 0.09), histology (P¼ 0.22), baseline EQ-5D
value X0.7 vs o0.7 (P¼ 1.00) and serum mesothelin falling vs
rising at visit 2 (P¼ 1.00).
DISCUSSION
The aim of this study was to investigate the effect of chemotherapy
on HRQoL in MPM, where scanty literature exists to inform
clinicians. HRQoL was formally assessed using a variety of disease-
specific and generic instruments. The EQ-5D is a generic HRQoL
instrument recommended by NICE for use in clinical trials but has
no published use in chemotherapy for MPM. The EQ-5D was able
to select out clinically distinct sub-groups and was associated with
overall survival and as such forms the basis of our more detailed
analysis.
Despite being advocated by NICE (NICE, 2008), the use of
chemotherapy for MPM is variable between centres across the UK
(HSCIC HaSCIC, 2014), due mainly to uncertainty about its
overall benefit. Pemetrexed and cisplatin is the only approved
Table 2. Compliance with HRQoL questionnaires
Chemotherapy
(n¼58), No. (%)
Comparator
(n¼15), No. (%)
Total
(n¼73), No. (%)
Visit 1 – baseline
Expected no. of forms 58 15 73
Received no. of forms 57 (98.3) 15 (100) 72 (98.6)
Visit 2–6 weeks
Expected no. of forms 58 15 73
Received no. of forms 45 (77.6) 15 (100) 60 (82.2)
Visit 3–16 weeks
Expected no. of forms 52 15 67
Received no. of forms 42 (80.8) 12 (80.0) 54 (80.6)
Visit 4–12 months
Expected no. of forms 45 12 57
Received no. of forms 26 (57.8) 7 (58.3) 33 (57.9)
Visit 5–18 months
Expected no. of forms 31 10 41
Received no. of forms 24 (77.4) 5 (50.0) 29 (70.7)
Abbreviation: HRQoL¼ health-related quality of life.
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Figure 1. Graph showing the change in mean EQ-5D between the
chemotherapy and comparator groups divided by histological
subtype.
BRITISH JOURNAL OF CANCER Quality of life in mesothelioma
1186 www.bjcancer.com |DOI:10.1038/bjc.2015.77
therapy following the results of a phase III clinical trial by
Vogelzang et al (2003) showing a survival benefit for combination
chemotherapy vs cisplatin alone (12.1 vs 9.3 months). Given that
the improvement in survival is small and the symptomatology
from MPM is severe, the focus of treatment remains palliative.
The majority of previous studies formally assessing HRQoL in
MPM have used the EORTC QLQ-C30 and/or LC13. Baseline data
from all studies demonstrates that patients are often in poor health
at study entry. Bottomley et al (2006) used these instruments in
250 patients receiving either raltitrexed and cisplatin or cisplatin
alone. Mean global health at baseline was around 55 (range 0–100)
and patients were impaired in all functional dimensions,
particularly role function, a characteristic of our cohort’s baseline.
The Bottomley and SWAMP cohorts were also comparable with
respect to symptom scales at baseline with significant fatigue, pain,
dyspnoea, insomnia and appetite loss. An RCT of video-assisted
thorascopic partial pleurectomy vs pleurodesis (MesoVATS trial) is
the only other published use of the EQ-5D in mesothelioma.
Interestingly, despite also using the EORTC QLQ-C30 and LC13,
the significant HRQoL findings were only apparent when analysing
the EQ-5D results (Rintoul et al, 2014).
As our study is not a randomised controlled trial, any
conclusions made comparing the differences between a che-
motherapy and self-selected comparator arm must be interpreted
with caution. The potential confounders of self-selection are
numerous. It is conceivable that the non-chemotherapy group were
not suffering from such distressing symptoms at baseline and felt
that the potential chemotherapy side effects outweighed the small
survival benefit. Such a confounder would significantly effect
HRQoL measures. Despite this, at baseline the groups were similar
with respect to overall quality of life and symptomatology. The
chemotherapy group reported predictable chemotherapy side
effects of nausea and vomiting, sore mouth and alopecia, all of
which have been reported in similar analyses (Bottomley et al,
2006). It is worth noting that the majority of performance and
symptom scales had improved by 16 weeks when treatment had
finished. Symptoms that persisted at 16 weeks have all been
previously associated with cisplatin, namely fatigue and alopecia
(Flechtner & Bottomley, 2003). The chemotherapy group reported
improvement in the symptoms of dyspnoea and arm pain, which
worsened significantly in the comparator group. Most notably, the
overall HRQoL assessed using the EQ-5D remained stable in the
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Figure 2. HRQoL dimensions with significant (Po0.01) changes from baseline between the chemotherapy and comparator groups. (A) QLQ-C30
Functional Scales. (B) QLQ-C30 Symptom Scales. (C) LC13 Symptom Scales.
Table 3. Impact of patient and tumour factors on HRQoL from baseline to 16 weeks
Factor
Mean EQ-5D
at baseline Change in EQ-5D from baseline to 16 weeks (ANCOVA)
Age 470 years (n¼ 20) 0.694 þ0.036
vs (P¼0.234)
Agep70 years (n¼22) 0.706 0.047
Epithelioid histology (n¼ 31) 0.715 þ0.032
vs (P¼0.012)
Nonepithelioid histology (n¼ 11) 0.661 0.110
Falling mesothelin at 6 weeks (n¼18) 0.662 þ0.085
vs (P¼0.049)
Rising mesothelin at 6 weeks (n¼22) 0.736 0.086
Neutrophil/leucocyte ratio o4 (n¼22) 0.719 0.053
vs (P¼0.291)
Neutrophil/leucocyte ratio 44 (n¼ 18) 0.672 þ0.045
Disease improvement on CT at 8 weeks (n¼6) 0.745 þ0.119
vs (P¼0.045)
Disease stable/progression on CT at 8 weeks (n¼35) 0.685 0.027
Abbreviations: ANCOVA¼ analysis of co-variance; CT¼ chemotherapy; HRQoL¼ health-related quality of life.
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chemotherapy group but declined significantly in the comparator
arm. At 16 weeks, the difference between the two was 0.20, greater
than the minimally important difference for lung cancer published
in the literature (Pickard et al, 2007). No EQ-5D literature exists
for comparison and few studies formally assessing HRQoL have a
comparator arm where no chemotherapy was used. Muers et al
(2004) randomised 409 patients into three separate groups,
including one group where no chemotherapy was given and two
others given mitomycin, vinblastine and cisplatin±vinorelbine.
Patients in this trial completed the QLQ-C30 and LC13 every
3 weeks up to 21 weeks. The investigators concluded that there was
no significant difference in quality of life between the groups.
Bottomley et al (2006) also found no difference between a
raltitrexed and cisplatin vs cisplatin alone regimen with respect to
overall HRQoL but did note that dyspnoea was improved in the
dual treatment arm.
In previous studies, patients with non-epithelioid disease had
poorer response to chemotherapy and survival (Neumann et al,
2004; Musk et al, 2011), but no study has linked histology to
HRQoL outcomes. We saw a significant decline in overall HRQoL
measured with the EQ-5D in patients with non-epithelioid
histology compared with epithelioid disease, from comparable
baselines. Despite the concurrent use of two disease-specific
instruments alongside the EQ-5D, it is not clear what symptoma-
tology contributes to this effect. Although the non-epithelioid
patients suffer from worse fatigue, cough and chest pain at 16
weeks, none of these differences are statistically significant. The
effect on overall HRQoL is likely to be a culmination of factors
that, due to smaller numbers of non-epithelioid disease and
complex symptomatology, this analysis cannot detect. Addition-
ally, this analysis found no evidence that chemotherapy was less
effective in non-epithelioid MPM.
Once chemotherapy is initiated, early markers of prognostication
and future HRQoL are useful for oncologists given variable
treatment response and side effect profile between patients. Serial
CT scanning using the modified RECIST criteria has been a
predictor of survival in previous studies and is often used to inform
future therapy but has never been correlated with later HRQoL. We
found that patients who had responded to chemotherapy at an
8-week CT scan had better HRQoL at later time points. However,
this only applied to a small proportion of the patients (17%, n¼ 6
out of 35) Additionally, these time-consuming investigations require
expert interpretation and can be made more difficult to interpret if
previous surgery or pleurodesis has been performed (Kwek et al,
2004). Several serum blood tests to augment radiological data have
been trialled, with variable success. Serum mesothelin has been
shown to be a useful biomarker of treatment response. Mesothelin is
a cell adhesion glycoprotein present on the surface of mesothelial
cells and is overexpressed in several malignancies, including MPM
(Creaney & Robinson, 2005). An early (2 months) falling mesothelin
has been correlated with survival and radiological treatment
response (primary SWAMP study) (Grigoriu & Scherpereel, 2008;
Creaney et al, 2011), but has never previously been linked to
HRQoL. Kao et al (2013) found that baseline VEGF, NLR and CRP
all correlated with dimensions in the Lung Cancer Symptom Scale.
Unfortunately, due to limited longitudinal data they could not make
any conclusions about changes in inflammatory markers and
response to treatment. Mesothelin is a simple serum blood test
which, if tested at an early clinic appointment, could be used as a
proxy for both better survival and maintenance of quality of life.
This study had several potential limitations that might weaken
our conclusions. As previously stated, the comparator group is
comprised of a small group of patients who although deemed fit for
chemotherapy declined it after an informed discussion with a
consultant oncologist. As they are self-selected, they cannot be
classed as a control group. They had similar performance and
HRQoL status at baseline but are older (although increasing age
was not related to poor HRQoL in this cohort) with a higher
proportion of females. Our finding that HRQoL is maintained in
the chemotherapy group compared with the comparator group
should be cautiously interpreted. Second, when analysing several
HRQoL instruments with numerous dimensions there is an
increased risk of type I errors. We therefore set a P-value of
o0.01 when assessing the QLQ-C30 and LC13 instruments, which
reduces the sensitivity of the analysis but strengthens the
conclusions. Finally, although a cohort of 73 patients suffering
from a rare disease is a good sample size, there was significant
attrition in questionnaire completion due to patient death and
falling compliance. To avoid survival bias and the bias introduced
by only including patients well enough to complete questionnaires,
we limited our analysis to time point 3 (16 weeks). At this point, an
assessment can be made of postchemotherapy functional status
with predicted resolution of chemotherapy-associated side effects.
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Figure 4. Change in mean EQ-5D values in patients receiving
chemotherapy divided by CT finding at 8 weeks.
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Figure 3. Change in mean EQ-5D values in patients receiving
chemotherapy with a falling vs rising mesothelin at 6 weeks.
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In summary, this study robustly assessed HRQoL in patients
receiving chemotherapy for MPM. Three validated questionnaires
were used with good compliance rates at baseline, during and after
chemotherapy, making this one of the most comprehensive
assessments of HRQoL in MPM literature. Based on this analysis,
patients who receive chemotherapy have better HRQoL outcomes
at 16 weeks compared with a self-selected comparator group, with
better dyspnoea and pain scores. In patients undergoing che-
motherapy, those with non-epithelioid histology have worse overall
HRQoL at later time points but this is likely due to more aggressive
disease. A falling mesothelin after two cycles of chemotherapy
predicts improved quality of life and was seen in 44% of patients.
Disease response on CT also predicts improved quality of life but
was observed more infrequently in this series. Clinicians can be
confident in the HRQoL benefits of continued chemotherapy given
either of these favourable markers at an early stage of treatment.
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